Reva Datar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Reva Datar has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Marcela F. Pasetti
Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA
2 shared publications - Marcelo B. Sztein
Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland
2 shared publications - Myron M. Levine
Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland
2 shared publications - Sharon M. Tennant
Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland
2 shared publications - Wilbur H. Chen
Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland
2 shared publications Yuanyuan Liang
Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland School of Medicine , Baltimore, Maryland
2 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e92156
Human-Centered Design of a Multistakeholder Reporting Dashboard for Disseminating HIV Implementation Research in the Ending the HIV Epidemic Initiative: Development and Formative Evaluation Study
Background: Interactive dashboards have expanded public access to HIV surveillance and programmatic data, but existing tools do not synthesize implementation research evidence into formats accessible to the diverse stakeholders who could use it. Designing such tools requires deliberate alignment with users’ needs, language, and decision-making contexts. Objective: We describe the human-centered design (HCD) process used to develop and conduct a formative evaluation of the Ending the HIV Epidemic (EHE) Implementation Science (IS) Reporting Dashboard, a public-facing tool intended to synthesize HIV implementation research conducted in EHE priority jurisdictions, and to identify generalizable lessons on translating IS evidence for diverse academic and nonacademic audiences. Methods: Guided by the Design Council’s Double Diamond framework, the Johns Hopkins HIV IS Hub used iterative Discover, Define, Develop, and Deliver phases to conceptualize, prototype, and refine the dashboard. Initial consultations with representatives from the National Institutes of Health and a national HIV IS coordination team identified 5 primary user groups: funders, academics, community partners, implementing partners, and domestic HIV IS experts. The Define phase used a purposeful working corpus of 15 EHE IS publications to develop a theory-informed, inductively refined extraction structure. From June 2024 to April 2025, we conducted 14 virtual user-testing sessions across 3 rounds, using purposeful recruitment through established professional networks. Round 1 included 4 academics; rounds 2 and 3 each included 5 participants, with 1 representative from each user group. Sessions used a semistructured dashboard walkthrough, were recorded and transcribed, and were analyzed by 3 team members using rapid qualitative analysis. Notes and transcript observations were organized into structured insight-translation tables and synthesized through team consensus meetings. Results: The HCD process produced a dashboard concept, a user-group and use-case framework, a data extraction architecture, wireframes, and a prototype organized around study design, populations, outcomes, and community engagement. User testing generated 5 cross-cutting themes: IS terminology created translation barriers; users needed clearer orientation to the dashboard’s purpose and audience; nonacademic users wanted plain-language, action-oriented summaries of research findings; representing community organizations and population affiliations required attention to consent and political sensitivity; and sustained use would require active dissemination beyond launch. These findings informed revisions to navigation, terminology, glossary features, plain-language study profiles, consent-based organization profiles, and dissemination planning. Conclusions: This study illustrates how HCD can inform both interface design and upstream evidence synthesis decisions when developing dissemination tools for implementation research. We offer practical lessons on translating IS evidence for diverse academic, public health, and community audiences.
- 30 July 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e92156
Open AccessHuman-Centered Design of a Multistakeholder Reporting Dashboard for Disseminating HIV Implementation Research in the Ending the HIV Epidemic Initiative: Development and Formative Evaluation Study
Background: Interactive dashboards have expanded public access to HIV surveillance and programmatic data, but existing tools do not synthesize implementation research evidence into formats accessible to the diverse stakeholders who could use it. Designing such tools requires deliberate alignment with users’ needs, language, and decision-making contexts. Objective: We describe the human-centered design (HCD) process used to develop and conduct a formative evaluation of the Ending the HIV Epidemic (EHE) Implementation Science (IS) Reporting Dashboard, a public-facing tool intended to synthesize HIV implementation research conducted in EHE priority jurisdictions, and to identify generalizable lessons on translating IS evidence for diverse academic and nonacademic audiences. Methods: Guided by the Design Council’s Double Diamond framework, the Johns Hopkins HIV IS Hub used iterative Discover, Define, Develop, and Deliver phases to conceptualize, prototype, and refine the dashboard. Initial consultations with representatives from the National Institutes of Health and a national HIV IS coordination team identified 5 primary user groups: funders, academics, community partners, implementing partners, and domestic HIV IS experts. The Define phase used a purposeful working corpus of 15 EHE IS publications to develop a theory-informed, inductively refined extraction structure. From June 2024 to April 2025, we conducted 14 virtual user-testing sessions across 3 rounds, using purposeful recruitment through established professional networks. Round 1 included 4 academics; rounds 2 and 3 each included 5 participants, with 1 representative from each user group. Sessions used a semistructured dashboard walkthrough, were recorded and transcribed, and were analyzed by 3 team members using rapid qualitative analysis. Notes and transcript observations were organized into structured insight-translation tables and synthesized through team consensus meetings. Results: The HCD process produced a dashboard concept, a user-group and use-case framework, a data extraction architecture, wireframes, and a prototype organized around study design, populations, outcomes, and community engagement. User testing generated 5 cross-cutting themes: IS terminology created translation barriers; users needed clearer orientation to the dashboard’s purpose and audience; nonacademic users wanted plain-language, action-oriented summaries of research findings; representing community organizations and population affiliations required attention to consent and political sensitivity; and sustained use would require active dissemination beyond launch. These findings informed revisions to navigation, terminology, glossary features, plain-language study profiles, consent-based organization profiles, and dissemination planning. Conclusions: This study illustrates how HCD can inform both interface design and upstream evidence synthesis decisions when developing dissemination tools for implementation research. We offer practical lessons on translating IS evidence for diverse academic, public health, and community audiences.
- 18 April 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (1) , 9-19
Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122
Background: There are no licensed vaccines to protect against Shigella or enterotoxigenic Escherichia coli (ETEC), yet they are among the most common causes of bacterial diarrhea. We engineered an attenuated Shigella flexneri 2a expressing colonization factor antigen 1 (CFA/I) and heat-labile enterotoxin B subunit (LTB) from ETEC and conducted a first-in-human randomized-controlled trial of ascending doses of the vaccine (CVD 1208S-122). Methods: Dose-escalating cohorts received a single oral dose of 108–1010 colony-forming units (CFU) of CVD 1208S-122 or placebo. A fourth cohort received 1 or 2 oral doses of 108 CFU CVD 1208S-122 or placebo. We measured the safety and clinical acceptability of the vaccine, genetic stability of fecally shed vaccine organisms, and immune responses elicited. Results: The 108 CFU doses were well tolerated (100%, 6/6). One recipient of 109 CFU (20%, 1/5) manifested diarrhea and 4 individuals who ingested 1010 CFU had either fever or diarrheal reactogenicity (67%, 4/6). Fecal shed vaccine organisms were genetically stable. Responses were observed to the lipopolysaccharide (LPS) and invasion plasmid antigen B (IpaB) of Shigella and CFA/I fimbriae and LTB of ETEC in serum, among antibody secreting cells, antibody in lymphocyte supernatant, and fecal samples. Serum antibodies exhibited Shigella bactericidal activity and inhibition of ETEC adherence in vitro. Conclusions: This study demonstrates safety with low-dose but unacceptable reactogenicity following highest-dose ingestion, genetic stability of all recovered fecal isolates, and immunogenicity of a prototype combined monovalent Shigella-ETEC vaccine. These results encourage expansion to a multivalent formulation to elicit broader protection against the most prevalent Shigella serotypes and ETEC CFA types that cause diarrheal disease. Clinical Trials Registration: NCT04634513.
- 18 April 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (1) , 9-19
Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122
Background: There are no licensed vaccines to protect against Shigella or enterotoxigenic Escherichia coli (ETEC), yet they are among the most common causes of bacterial diarrhea. We engineered an attenuated Shigella flexneri 2a expressing colonization factor antigen 1 (CFA/I) and heat-labile enterotoxin B subunit (LTB) from ETEC and conducted a first-in-human randomized-controlled trial of ascending doses of the vaccine (CVD 1208S-122). Methods: Dose-escalating cohorts received a single oral dose of 108–1010 colony-forming units (CFU) of CVD 1208S-122 or placebo. A fourth cohort received 1 or 2 oral doses of 108 CFU CVD 1208S-122 or placebo. We measured the safety and clinical acceptability of the vaccine, genetic stability of fecally shed vaccine organisms, and immune responses elicited. Results: The 108 CFU doses were well tolerated (100%, 6/6). One recipient of 109 CFU (20%, 1/5) manifested diarrhea and 4 individuals who ingested 1010 CFU had either fever or diarrheal reactogenicity (67%, 4/6). Fecal shed vaccine organisms were genetically stable. Responses were observed to the lipopolysaccharide (LPS) and invasion plasmid antigen B (IpaB) of Shigella and CFA/I fimbriae and LTB of ETEC in serum, among antibody secreting cells, antibody in lymphocyte supernatant, and fecal samples. Serum antibodies exhibited Shigella bactericidal activity and inhibition of ETEC adherence in vitro. Conclusions: This study demonstrates safety with low-dose but unacceptable reactogenicity following highest-dose ingestion, genetic stability of all recovered fecal isolates, and immunogenicity of a prototype combined monovalent Shigella-ETEC vaccine. These results encourage expansion to a multivalent formulation to elicit broader protection against the most prevalent Shigella serotypes and ETEC CFA types that cause diarrheal disease. Clinical Trials Registration: NCT04634513.
- 26 March 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (6) , 1081-1090
Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine to S. Typhi, S. Typhimurium, and S. Enteritidis
Invasive disease caused by typhoid and nontyphoidal Salmonella (NTS) is a threat confronting young children in sub-Saharan Africa. We are developing a trivalent Salmonella conjugate vaccine (TSCV) consisting of typhoid Vi conjugate and core-O-polysaccharide conjugates from 2 invasive NTS serovars (S. Typhimurium and S. Enteritidis). We conducted a randomized-controlled Phase 1/2a trial assessing the safety and immunogenicity of a full-strength TSCV (FS; 25 µg of all 3 polysaccharides), half-strength TSCV (HS; 25 µg of Vi and 12.5 µg of both NTS polysaccharides), dilutional half-strength TSCV (dilHS; 12.5 µg of all 3 polysaccharides), or placebo. Local and systemic adverse events were recorded and blood was collected for serum antibody and antibody-secreting cells (ASCs). In total, 80 evaluable participants aged 20–47 years were enrolled. All vaccines were well tolerated; mild injection site pain and fatigue were the most common reactions reported. Serum antibody and ASC responses to the 3 primary polysaccharide antigens were robust, ranging between 85% and 100% response rates, with no statistically significant difference between the 3 formulations. No placebo recipients manifested significant antibody or ASC responses. These data encourage the further development of TSCV to address a pressing public health problem in young children of sub-Saharan Africa.
- 26 March 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (6) , 1081-1090
Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine to S. Typhi, S. Typhimurium, and S. Enteritidis
Invasive disease caused by typhoid and nontyphoidal Salmonella (NTS) is a threat confronting young children in sub-Saharan Africa. We are developing a trivalent Salmonella conjugate vaccine (TSCV) consisting of typhoid Vi conjugate and core-O-polysaccharide conjugates from 2 invasive NTS serovars (S. Typhimurium and S. Enteritidis). We conducted a randomized-controlled Phase 1/2a trial assessing the safety and immunogenicity of a full-strength TSCV (FS; 25 µg of all 3 polysaccharides), half-strength TSCV (HS; 25 µg of Vi and 12.5 µg of both NTS polysaccharides), dilutional half-strength TSCV (dilHS; 12.5 µg of all 3 polysaccharides), or placebo. Local and systemic adverse events were recorded and blood was collected for serum antibody and antibody-secreting cells (ASCs). In total, 80 evaluable participants aged 20–47 years were enrolled. All vaccines were well tolerated; mild injection site pain and fatigue were the most common reactions reported. Serum antibody and ASC responses to the 3 primary polysaccharide antigens were robust, ranging between 85% and 100% response rates, with no statistically significant difference between the 3 formulations. No placebo recipients manifested significant antibody or ASC responses. These data encourage the further development of TSCV to address a pressing public health problem in young children of sub-Saharan Africa.